| Literature DB >> 31969252 |
Brian Slomovitz1, Charlie Gourley2, Mark S Carey3, Anais Malpica4, Ie-Ming Shih5, David Huntsman6, Amanda N Fader5, Rachel N Grisham7, Matthew Schlumbrecht8, Charlotte C Sun9, Jane Ludemann10, Gail Austin Cooney11, Robert Coleman12, Anil K Sood12, Haider Mahdi13, Kwong K Wong12, Allan Covens14, David M O'Malley15, Fabrice Lecuru16, Lauren P Cobb12, Thomas A Caputo17, Taymaa May18, Marilyn Huang8, John Siemon8, Marta Llauradó Fernández3, Isabelle Ray-Coquard19, David M Gershenson12.
Abstract
In January 2019, a group of basic, translational, and clinical investigators and patient advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade serous carcinoma of the ovary or peritoneum-a rare ovarian cancer subtype that may arise de novo or following a diagnosis of serous borderline tumor. The purpose of the conference was to review current knowledge, discuss ongoing research by established researchers, and frame critical questions or issues for future directions. Following presentations and discussions, the primary objective was to initiate future collaborations, uniform database platforms, laboratory studies, and clinical trials to better understand this disease and to advance clinical care outside the boundaries of single academic institutions. This review summarizes the state of the science in five principal categories: epidemiology and patient outcomes, pathology, translational research, patient care and clinical trials, and patients' perspective.Entities:
Keywords: Epithelial ovarian cancer; Low-grade serous carcinoma of the ovary; Low-grade serous carcinoma of the peritoneum
Year: 2020 PMID: 31969252 DOI: 10.1016/j.ygyno.2019.12.033
Source DB: PubMed Journal: Gynecol Oncol ISSN: 0090-8258 Impact factor: 5.482